BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
Traveling Alone: An Excursion of Self-Disclosure- Step by step instructions to Recognize the Distinction Between Lab Jewels and Precious stone Simulants
- Russia Creates New Military Branch Dedicated To Drone Warfare
- Ethiopian earthquakes and volcanic eruptions: earth scientist explains the link
- Wedding Guest Outraged That Bride and Groom, Who Are in Their 60s and Have Both Been Married Before, Registered for Gifts
- Get To Be familiar with The Historical backdrop Of Western Medication
- Pilot captures jaw-dropping northern lights show from 36,000 feet (photos)
- New York to require social media platforms to display mental health warnings
- 5 Different ways Macintosh is Prepared to Overwhelm Gaming, Even Against Windows
